19 and 20+ B Cell Hematologic Tumors
1 clinical trials · Condition
◉ Watch 19 and 20+ B Cell Hematologic Tumors
| Record | Firm | Date |
|---|---|---|
| To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors (NCT05388695) | Hebei Senlang Biotechnology Inc., Ltd. | 2022-04-08 |
Track 19 and 20+ B Cell Hematologic Tumors automatically
Every clearance here is in the API, with alerts when new ones post.